Predicting poor vaccine responders to Hepatitis B vaccination

Go Back to All Clinical Trials

Predicting poor vaccine responders to Hepatitis B vaccination

Brief description of study

Hepatitis B vaccines are indicated broadly for the prevention of hepatitis B infection, yet the vaccine is not uniformly effective in all individuals. We need better understanding of the relevant T and B immunology of the vaccine response to understand why some people respond better than others. Recently, an adjuvanted hepatitis B vaccine was approved that leads to better immune responses with fewer doses. Here, we seek to understand 1) what is the immunological difference between vaccine responders and nonresponders, and 2) what is the difference in the immune responses generated by the adjuvanted vaccine and with the nonadjuvanted vaccine? By focusing on the T and B cell responses in peripheral blood, we will study the generation, maintenance, and longevity of the immune response in those who respond well versus those who do not respond well.

Clinical Study Identifier: s20-01782

ClinicalTrials.gov Identifier: NCT04674462

Principal Investigator: Ramin Herati.

Other Investigator: Mark J. Mulligan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies